Literature DB >> 16944075

[Heparin-induced thrombocytopenia].

K Gürtler1, I Euchner-Wamser, G Neeser.   

Abstract

Heparins are in widespread use as anticoagulants for the prophylaxis and therapy of thromboembolisms. A dangerous side-effect is heparin-induced thrombocytopenia type II (HIT type II) with the paradox of thromboembolic venous and arterial vascular occlusions. HIT type II is an immunological disease which results in activation of platelets and plasma coagulation. The main symptom is an acute onset of thrombocytopenia with a fall in thrombocytes to less than 50% of the initial value with or without newly arising thromboembolic complications between days 5 and 14 after the start of heparin therapy. Surgery patients are more often affected by subclinical antibody formation as well as by symptomatic HIT type II than clinical patients. In this review we will discuss the difficult diagnosis and the differential diagnosis with special emphasis on postoperative intensive care patients, as well as preventive measures and management on occurrence of HIT type II and associated thrombotic complications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16944075     DOI: 10.1007/s00101-006-1072-x

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  29 in total

1.  [Anticoagulation for HIT II: When should it be used therapeutically and when as prophylaxis?].

Authors:  A Greinacher
Journal:  Anasthesiol Intensivmed Notfallmed Schmerzther       Date:  2002-04       Impact factor: 0.698

2.  Heparin-induced thrombocytopenia in open heart surgical patients: sequelae of late recognition.

Authors:  J T Walls; J J Curtis; D Silver; T M Boley; R A Schmaltz; W Nawarawong
Journal:  Ann Thorac Surg       Date:  1992-05       Impact factor: 4.330

Review 3.  Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia.

Authors:  L M Kondo; A K Wittkowsky; B S Wiggins
Journal:  Ann Pharmacother       Date:  2001-04       Impact factor: 3.154

4.  Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.

Authors:  A Greinacher; U Janssens; G Berg; M Böck; H Kwasny; B Kemkes-Matthes; P Eichler; H Völpel; B Pötzsch; M Luz
Journal:  Circulation       Date:  1999-08-10       Impact factor: 29.690

Review 5.  New approaches to the diagnosis of heparin-induced thrombocytopenia.

Authors:  Theodore E Warkentin
Journal:  Chest       Date:  2005-02       Impact factor: 9.410

Review 6.  The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy.

Authors:  Kathryn Hassell
Journal:  Chest       Date:  2005-02       Impact factor: 9.410

7.  Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series.

Authors:  Gregory A Nuttall; William C Oliver; Paula J Santrach; Robert D McBane; Daniel B Erpelding; Christina L Marver; Kenton J Zehr
Journal:  Anesth Analg       Date:  2003-02       Impact factor: 5.108

8.  Multiple coronary artery graft occlusion in a fatal case of heparin-induced thrombocytopenia.

Authors:  A P Burke; T Mezzetti; A Farb; E R Zech; R Virmani
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

9.  Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

Authors:  Bruce E Lewis; Diane E Wallis; Fred Leya; Marcie J Hursting; John G Kelton
Journal:  Arch Intern Med       Date:  2003 Aug 11-25

10.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

Authors:  T E Warkentin; M N Levine; J Hirsh; P Horsewood; R S Roberts; M Gent; J G Kelton
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

View more
  1 in total

1.  [Dermal necrosis as cutaneous manifestation of heparin-induced thrombocytopenia II?].

Authors:  M Illes; S Klaus; J C Simon; R Treudler
Journal:  Hautarzt       Date:  2011-04       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.